Select Page

Shift Health was engaged by a leading US investment firm to evaluate an asset and project sales in order to inform their decision to invest in an established biotechnology company expanding into new markets.

Working under tight timelines to make a decision, the firm required support to evaluate technical, development and commercial risks and to determine the future potential of a new cancer vaccine in late-stage clinical trials. Shift Health conducted extensive secondary research of public and proprietary information and engaged key opinion leaders to determine the value proposition for the new vaccine in addressing unmet patient needs, the competitive advantages offered versus existing or upcoming products and the capacity of a partner organization’s sales force to expand globally. We then determined risk-adjusted and manufacturing-limited future sales estimates as well as the net present value of the asset and the associated manufacturing facility.

Armed with a sound liquidation valuation of the asset, the investment firm was able to confidently pull the trigger on a significant investment in the biotech company.